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Abstract
Almost all prostate cancers respond to androgen deprivation treatment but many recur. We postulated that risk of hormone
escape -frequency and delay- are influenced by hormone therapy modalities. More, hormone therapies induce crucial
biological changes involving androgen receptors; some might be targets for escape prevention. We investigated the
relationship between the androgen deprivation treatment and the risk of recurrence using nude mice bearing the high
grade, hormone-dependent human prostate cancer xenograft PAC120. Tumor-bearing mice were treated by Luteinizing-
Hormone Releasing Hormone (LHRH) antagonist alone, continuous or intermittent regimen, or combined with androgen
receptor (AR) antagonists (bicalutamide or flutamide). Tumor growth was monitored. Biological changes were studied as for
genomic alterations, AR mutations and protein expression in a large series of recurrent tumors according to hormone
therapy modalities. Therapies targeting Her-2 or AKT were tested in combination with castration. All statistical tests were
two-sided. Tumor growth was inhibited by continuous administration of the LH-RH antagonist degarelix (castration), but
40% of tumors recurred. Intermittent castration or complete blockade induced by degarelix and antiandrogens
combination, inhibited tumor growth but increased the risk of recurrence (RR) as compared to continuous castration
(RRintermittent: 14.5, RRcomplete blockade: 6.5 and 1.35). All recurrent tumors displayed new quantitative genetic alterations and
AR mutations, whatever the treatment modalities. AR amplification was found after complete blockade. Increased
expression of Her-2/neu with frequent ERK/AKT activation was detected in all variants. Combination of castration with a Her-
2/neu inhibitor decreased recurrence risk (0.17) and combination with an mTOR inhibitor prevented it. Anti-hormone
treatments influence risk of recurrence although tumor growth inhibition was initially similar. Recurrent tumors displayed
genetic instability, AR mutations, and alterations of phosphorylation pathways. We postulated that Her-2/AKT pathways
allowed salvage of tumor cells under castration and we demonstrated that their inhibition prevented tumor recurrence in
our model.
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Introduction
Androgen receptor (AR) controls cell proliferation and survival
in the normal prostate and prostate carcinomas (PCa). Thus
androgen deprivation is first-line treatment of PCa. Hormone
therapy includes castration pharmacologically achieved with
luteinizing-hormone releasing hormone (LH-RH) agonists or
antagonists, AR antagonists as flutamide or bicalutamide or new
treatment modalities such as inhibitor of 17–20 lyase (abiraterone
acetate, TAK700) or MDV3100 [1]. Treatments are given
continuously or intermittently, by LH-RH inhibitor monotherapy,
antiandrogen monotherapy or combined as referred to complete
androgen blockade.
Whatever the hormone therapy, most tumors respond then
acquire androgen independence and recur [2,3]. Several mechan-
isms have been proposed [4,5]. i. Genomic changes occur during
tumor progression but their role remains unclear, although clonal
chromosome abnormalities have been found in PCa [6,7]. ii.
Alteration of AR expression is frequent due to gene amplification
[8], increased transcription, or stabilization of the AR protein via
phosphorylation of specific AR residues [9,10], AR mutations that
broaden the ligand spectrum [8], alterations in nuclear receptor
coactivators, and ligand-independent binding of AR to DNA [2,11].
The prevalence and influence of AR alterations on disease
progression are not known because of the variability in treatment
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regimens, limited access to material from patients and thus few
comprehensive sequencing studies. iii. Activation of survival path-
ways is involved in hormone escape [12], such as Her-2/neu (a
growth factor receptor tyrosine kinase), mTOR/AKT (target of
rapamycin/AKT), or ERK1,2 (extracellular-signal-regulated ki-
nase), all implicated in AR phosphorylation [5,10]. Her-2/neu
expression is usually low in PCa. However, high levels of Her-2/neu
were found associated with shortened survival times in a subset of
PCa patients [13,14]. More, Craft et al. showed that forced Her-2/
neu expression modulates AR signaling and leads to androgen
independence [15]. An altered AKT pathway was associated with
PCa progression and the emergence of AI tumors [16]. Moreover,
Graff et al. showed that forced overexpression of AKT in LNCaP cell
line accelerated tumor growth [17]. AKT might be an alternative
way by which Her-2/neu leads to outlaw AR activation [18].
A key question in clinics is whether modalities of hormone
treatment differently affect the risk of escape. To respond to this
critical question, we used an experimental model of a hormone
dependent of human prostate cancer (PAC120), derived directly
from a patient and growing in immunodeficient mice. We
evaluated the effect of different hormone treatment modalities
on the immediate response and on the risk of recurrence; the
biological changes associated with different treatments, as genome
alterations, AR mutations, and growth factor expression/activation
were studied. The involvement of phosphorylation pathways in
hormone escape led us to test combination of tyrosine kinase
inhibitors with pharmacological castration to reduce the risk of
tumor recurrence.
Methods
Prostate Tumor Xenografts
PAC120, a hormone-dependent human-in-mouse PCa xeno-
graft, [19] maintained by serial transplantation into the inter-
scapular fat pad of male Swiss nude mice (Crl:NU(Ico)-Foxnlnu)
from Charles River (L’Arbresle, France) was used between
passages 47 and 51. Tumor pieces of 20 mm365 (620. 106 cells)
where transplanted. All protocols followed institutional guidelines
as put forth by the French Ethical Committee.
Treatments
degarelix (FirmagonH known as FE 200486 during it de-
velopment, Ferring Research Institute Inc., San Diego, CA) [20]
injected subcutaneously monthly at 10 mg/kg [19], bicalutamide
(CasodexH, Astra Zeneca, France) and flutamide (EulexineH,
Schering-Plough, Kenilworth, N.J.) given at 50 mg/kg, per os,
5 days per week. Trastuzumab (HerceptinH, Roche, France)
injected weekly at 10 mg/kg via intraperitoneal administration.
Everolimus (AfinitorH, Novartis Pharma AG, Switzerland) given
per os at 2 mg/kg, 3 days per week. We define continuous
castration as injection of degarelix alone once a month. Mice were
kept under treatment until the relapse of the tumor (tumor had to
reach a 1500 mm3). Intermittent castration consisted of 2
injections of degarelix at day 0 and 28 (one cycle), then stopped
the treatment until the tumor reach back 2 times the initial
volume. The complete androgen blockade is the association of
degarelix monthly in combination with the anti-androgen receptor
inhibitor (either bicalutamide or flutamide). Figure S1 represents
a schematic diagram of the treatments modalities.
Tumor Growth Assessment
Follow-up of tumor growth was done according to Marangoni
et al. [21]. Recurrence was defined as the time in days required for
tumors to achieve a 5-fold increase from initial volume.
PAC120 xenograft tumor fragments were randomly implanted
into 204 male mice. As soon as tumors reached a mean volume of
63–250 mm3, mice were assigned to treatment (n indicated in
Table S1). After tumor regrowth, AI tumors were transplanted
into pharmacologically castrated male mice and characterized at
early passages (1 to 4).
RT-PCR mRNA Analysis
Total RNA was extracted as previously published [21].
Sequences of primers are indicated in the Methods S1.
Functional AR Mutation Detection by ADE2 Reporter
Assay
We used a functional assay in the EJ250 yeast strain to detect
AR mutations [22].
Androgen receptor (AR) yeast-based activity assay. An
AR activity assay performed in the recombinant EJ250 yeast
strain (MATa ade2-101 his3-D200 leu2-D1 lys2-801 trp1-D1
ura3-52 URA3: ARE-ADE2[pRS/AREAde2]) was used to
screen tumor samples for AR mutations as previously described
[22,23]. In this EJ250 yeast strain, the expression of the ADE2
reporter gene, necessary for adenine biosynthesis, was placed
under the tight control of an androgen-dependent promoter
[22]. Consequently, EJ250 yeast growth relies on the transcrip-
tional activity of a ligand-activated androgen receptor. After
transformation with an AR expression plasmid as described
earlier [22], yeast were plated on selective media depleted of
adenine and containing either dihydrotestosterone (DHT),
dehydroepiandrostenedione, b-estradiol, progesterone, 17a´-hy-
droxyprogesterone, flutamide or cyproterone acetate (Sigma
Aldrich, St Quentin Fallavier, France) at the indicated
concentration. A negative control (vehicle) and a positive control
(supplemented with adenine) were also included. When applied
to tumor samples, mutated AR variants can be distinguished
from wild type AR according to their response to the steroid or
nonsteroid molecule added in the medium.
Detection of androgen receptor (AR) mutations in tumor
samples. Briefly, total RNA was prepared from tumor samples
(RNeasy Midi Kit, Qiagen, Courtaboeuf, France). Reverse
transcription was performed with the Omniscript reverse tran-
scription kit (Qiagen) from 1 mg of total RNA. AR cDNA
fragments were amplified with the forward (59-
TGCGGCGGCGCAGTGCCGCTAT-39) (nucleotides 2310–
2339) and reverse (59-GGTGCCATGGGAGGGTTAGATAGG-
GAG-39) (nucleotides 4075–4101) primers flanking exons 1–8
(GenBank NM_000044.2, nucleotides 2310–4101). Thereafter,
100 ng AR cDNAs fragments were inserted into a yeast expression
‘‘gap repair’’ plasmid by homologous recombination, and after
plating and incubation at 30uC for 72 h, yeast colonies were
scored [22]. The wild-type AR was assayed in parallel as
experimental control. The androgen receptor-dependent yeast
growth in response to the steroid or antiandrogen added to the
medium was evaluated by colonies scoring. Data are presented as
histograms corresponding to the ratio of the number of yeast
colonies scored to the number of colonies obtained in the presence
of 100 nM DHT. For AR mutations characterization, the AR
expression plasmid was rescued from yeast cells for sequencing.
Briefly, yeasts were lysed with 150 to 212 mm acid-washed glass
beads (Sigma Aldrich) and plasmid DNA was extracted with the
Nucleospin plasmid kit (Macherey-Nagel, Hoerdt, France) and
processed for sequencing (GATC Biotech AG, Konstanz,
Germany).
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Protein Expression Analyzed by Western Blotting
AKT, phospho-AKT (S473), ERK1/2 (Cell Signaling Tech-
nology, Ozyme, Saint Quentin en Yveline, France), and PSA
(Dako) were used at 1:1000. Her-2/neu (Cell Signaling), AR
(Upstate, Millipore, Saint Quentin en Yveline), and p-ERK1/2
(RnD systems, Lille, France) were used at 1:500. Anti-beta-actin
was used at 1:5000 (Sigma-Aldrich, Saint Quentin Fallavier,
France). Protocols are detailed in Methods S1.
Comparative Genomic Hybridization Arrays
Procedure was previously published [24]. We performed co-
hybridization between the DNA extracted from AI variants and
those from PAC120p47. Minimal common alterations were
identified [25]. Hierarchical clustering was performed on profiles
based on minimal regions. Euclidian distance was used as the
similarity measure and the Ward algorithm as the agglomerative
method. Separation into groups was proposed on the basis of the
structure of the dendrogram.
Histology
Light microscope histology studies used 4-mm-thick formalin
fixed paraffin-embedded sections from PAC120, PAC120 residual
tumors and AI variants stained with hematoxylin and eosin safran.
Statistical Analysis
We used the Mann-Whitney test, Kaplan-Meier survival plots,
log-rank tests, and the Fisher’s exact test, according to respective
experiments as detailed in Methods S1.
Results
In vivo Response to Hormone Treatment Regimens
Continuous castration by degarelix arrested the growth of all
PAC120 tumors. Recurrences were observed in 8/20 mice, in
a median delay of 274 days [range 211–323] (Figure 1A).
Intermittent castration was tested according to the following
protocol: The first administration of degarelix reduced tumor
volume in all animals (14/14, 100%). The second administration
was given once tumor regrew of two-fold in volume, in a median
delay of 119 days. Six tumors such treated did not respond (6/14,
43%) and 8 showed low response or stabilization. Kaplan Meier
analysis showed an increased relative risk of recurrence of 14.5
(95% CI: 2.98–70.9, p,0.001, log-rank test) (Figure 1A and Table
S2). Therefore, intermittent androgen deprivation increased the
risk of recurrence and reduced time to progression as compared
with continuous castration.
Flutamide or bicalutamide significantly delayed tumor growth
(p = 0.03, and p,0.001, respectively) (Figure 1B). Complete
androgen blockade (degarelix plus bicalutamide) arrested tumor
growth in 30 treated cases but 24 tumors recurred. Recurrences
occurred earlier than after castration alone (Table S2) with
increased relative risk of recurrence (relative risk of 6.55; 95% CI:
2.41–17.8, p,0.001, log-rank test) (Figure 1A and Table S2).
Complete androgen blockade with degarelix plus flutamide led to
8/11 recurrent tumors and a median time to hormone escape of
253 days [range 43–337] (Table S2); increase of recurrence risk
was not statistically significant as compared with degarelix alone
(p = 0.561, log-rank test).
Histological and Molecular Alterations Associated with
Androgen Independence
Residual PAC120 tumors under castration showed necrotic
areas, numerous mitoses and no apoptotic bodies (Figure 1C ii
& iii). Androgen independent (AI) variants displayed histological
changes, such as mucinous, neuroendocrine-like, or adenoid
differentiation features (Figure 1C iv–vi). All AI variants
displayed mixed patterns, dominated by mucinous differentia-
tion or/and apocrine differentiation and numerous multinuclear
cells. None features were specific to any particular hormone
treatment.
The chromosomal stability of PAC120 tumors through time and
passages has been previously demonstrated [24]. We co-hybrid-
ized AI DNA with the parental PAC120 DNA to reveal the new
alterations. Thirty-five minimal regions were altered in at least 5
(20%) of the 26 AI variants studied. Surprisingly, none of the
alterations were common to all AI variants. Gene copy gains and
losses are detailed in Table S3. The 26 AI variants were grouped
by altered regions into five distinct groups using a hierarchical
cluster analysis (Figure 2). However, we did not find any
treatment-specific pattern of alterations associated with recur-
rences (Fisher exact test and Benjamini and Hochberg correction
to adjust for multiple testing). These results show that androgen
deprivation generated a random diversity of new genetic
alterations but no specific pattern could be attributed to the type
of treatment regimen. These alterations were stably acquired (data
not shown).
AR gene amplification was observed in 15% (4/26) of AI
variants and occurred only in the AI derived after complete
blockade (AIde-a) group (Table S3). Frequency of gene amplifi-
cation after complete androgen blockade was significantly higher
than after castration alone (p = 0.01, Fisher exact test). In these
cases AR mRNA levels were increased of 10 to 20-fold, as were
intratumoral PSA mRNA levels (Figure S2).
AR mutations were detected using a functional yeast-based assay
as described previously [22]. No functional AR mutations were
found in the PAC120 tumor but appeared in 28% (10/36) of AI
variant tumors. An example of the profile that we obtained for
AIde-a4 is shown in the Figure S3. Mutations occurred in 46%,
17%, and 25% after complete blockade, antiandrogens and
degarelix, respectively (Table S4). AR cDNA sequencing revealed
30 different AR mutations (Figure 3, Table 1), of which 70% were
located in the hinge region (HR) or in the ligand binding domain
(LBD), 27% led to a truncated AR protein. Some AI variants
displayed several mutations. Only Q693X was common to all of
the different hormone treatments. The Q693X mutation, as well
as the other premature stop codons in Table 1, leads to a truncated
AR variant lacking the ligand-binding domain and AF-2. The
Q693X AR variant has also been detected in human prostate
cancer tumors (unpublished data). Truncated AR variants
demonstrate constitutive transcriptional activities as previously
reported [23]. They have been associated with castration-
resistance as they can promote prostate cancer cell growth in vitro
cell cultures and animal tumor models in the absence of androgens
(Figure S4). Most mutations were novel.
The AR protein level (normalized by actin) was increased in all
AI variants (Figure 4). These data suggest that AR alterations are
key events in tumor recurrence after androgen deprivation,
required for prostate cancer cell survival.
Her-2/neu protein was overexpressed in all AI variants (n = 17)
tested as compared with PAC120 (Figure 4). In addition, AKT or
ERK1,2 or both pathways were activated in the majority of AI
variants, showing that such an activation is associated with escape
to hormone deprivation, and participates compensatory mechan-
isms of AR activation. The key role of these phosphorylation
pathways was indirectly demonstrated by the strong effect of their
inhibition.
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Effects of Combination Castration with Tyrosine Kinase
Inhibitors
Degarelix combined with trastuzumab significantly and drasti-
cally reduced the relative risk of recurrence to 0.17 (95% CI: 0.04–
0.67, p = 0.005, log-rank test) (Figure 5A), and prolonged the
median time to hormone escape from 274 to 351 days (Table S2)
versus castration with degarelix alone. Tumor recurrence was
observed in only 17% (4/24) of animals receiving the combination
treatment. Trastuzumab as a single agent had no effect on the
tumor growth.
Figure 1. PAC120 xenograft tumor response to androgen deprivation treatment regimens. A) Kaplan-Meier analysis of hormone escape-
free survival after continuous (white square, full line), intermittent (white square, dotted line) degarelix, bicalutamide plus degarelix (black triangle,
full line) or flutamide plus degarelix (black triangle, dotted line). B) Tumor growth curves as a function of time in control (white cercle, full line),
bicalutamide (white triangle, full line), flutamide (white triangle, dotted line),degarelix (white square, full line), bicalutamide plus degarelix (black
triangle, full line) and flutamide plus degarelix (black triangle, dotted line); C i) PAC120 xenograft [x200], residual PAC120 tumor (300 days) ii)[x100],
iii) [x400], AI variants with adenoid features (iv) [x100], amphicrine features (v) [x200], and mucosecretant features (vi) [x200].
doi:10.1371/journal.pone.0042252.g001
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Degarelix combined with everolimus completely prevented
hormone escape of the 17 tumors treated. As single-agent
everolimus delayed tumor growth and the TGI36 days was 59%
(p = 0.001, Mann-Whitney) (Figure 5B).
These results demonstrate a superior effect of castration when
combined with HER-2/neu targeting antibodies or mTOR in-
hibitor.
Discussion
We conducted an in vivo experimental study of the effect of
different hormone treatments on the risk of hormone escape. We
established a large series of AI variants to study the diversity of
genetic and molecular events occurring after hormone escape. We
used an hormone-dependent human PCa xenograft (PAC120)
[19]. PAC120 derived directly from a primary tumor of a patient.
PAC120 showed striking karyotype stability, maintained stable
hormone dependence [24] and lack of AR mutations, after
multiple passages [19].
Continuous pharmacological castration arrests tumor growth,
escapes occur in 40% of cases. Antiandrogen monotherapy slowed
down tumor growth. This reflects the clinical observations. In our
model, complete androgen blockade increased the risk of hormone
escape, as compared with castration alone. It seems that complete
androgen blockade exerts a high pressure on the AR signaling
pathway, leading to the activation of several survival pathways.
Large randomized studies and meta-analyses showed that
complete blockade did not prolong the time to progression in
most patients [26]. Phase II and III studies comparing intermittent
versus continuous castration in prostate cancer were associated
with a higher risk of hormone escape in case of intermittent
castration, but overall survival was not shortened after intermittent
androgen deprivation in comparison with a continuous schedule
with a better quality of live and less cost [27,28]. The discrepancy
with our data could be explained by the aggressiveness of PAC120
Figure 2. Unsupervised hierarchical clustering analysis on gene copy number alterations. There was no relationship between gene copy
number alterations and the type of hormone treatment. The left hand column indicates numbered AI variants by treatment where de denotes
degarelix, de-a degarelix plus antiandrogen (bicalutamide or flutamide), de-t degarelix plus trastuzumab. Green and red colors correspond to losses
and gains of gene copy number, respectively. Yellow corresponds absence of difference in terms of gene copy number between AI variants and
parental PAC120 DNA.
doi:10.1371/journal.pone.0042252.g002
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(Gleason 9), whereas the clinical studies included a large diversity
of prostate tumors of low and high grade. More, the time chosen to
restart the treatment was based on a unic parameter, i.e. tumor
volume, while in clinic several parameters are considered
(testosteronemia, PSA). Intermittent therapy might be not
appropriate to all cases of prostate cancers.
AI variants displayed biological changes. Histology of tumors
under castration showed numerous mitosis and necrotic areas,
Figure 3. AR gene sequence showing mutations detected in AI variants A) after treatment with single-agent degarelix, B) after
antiandrogens and C) after complete androgen blockade. Full underlines show mutations found in more than one tumor treated with the
same agent. Mutations depicted with a blue, green or red background have previously been described in PAIS, CAIS and PCa, respectively.
doi:10.1371/journal.pone.0042252.g003
Table 1. Classification of androgen receptor mutations detected.
Functional consequences Mutations
Constitutively active AR variants K632X; Q640X; G644X; Q670X; Q693X; L700X; G708X; R710X; R711X; W718X; W796X
Promiscuous AR variants T877A
Unknown functions T438A; M507A; S529G; S529N; R629Q; S647G/S791Y; F673I; F725S; V726A; Q738R; G750D;
R774H; S778F; W796L; S854L; A870V
doi:10.1371/journal.pone.0042252.t001
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suggesting a balance between mitosis/cell survival/death and
dismissing any dormant state of tumoral residue. AI variants
displayed mixed patterns, mucinous or/and apocrine differentia-
tion similar to the parental tumor and none features specific to
hormone treatment modality.
We checked that the deeply altered karyotype of PAC120
remained quite stable through transplantation and time [24], and
we showed that castration resulted in a wave of new genomic
alterations. More, these acquired alterations are stable (data not
shown) perhaps explaining why hormone independence was
irreversibly acquired. Surprisingly none of the new alterations
were common to the 26 AI variants. Genetic instability is known to
be linked to cancer progression, our observation suggests such
a progression mechanism [29,30]. Then we searched for
alterations involving AR expression, gene amplification or genetic
mutations. AR gene amplifications, were detected after complete
androgen blockade as found in patients [31]. AR mutations which
contribute to hormone escape by providing a larger receptivity of
Figure 4. Protein expression of the androgen receptor (AR), human epidermal growth factor receptor 2 (Her-2/neu) and ratios of
pAKT/AKT and pERK/ERK detected using A) Western blotting analysis in androgen-independent (AI) variants. Actin was used as
a control for loading protein. B) Histograms representing the quantification of AR, Her-2/neu and ratios of pAKT/AKT and pERK/ERK normalized to
actin and mean of PAC120 coming from various passages (expressed arbitrary units). AR (black bars) was expressed in PAC120 and all AI variants and
Her-2/neu (dotted grey bars) was overexpressed in all AI variants. Either p-AKT/AKT (grey bars with full line) or pERK/ERK (white bars) were activated
in AI variants. Abbreviations used to identify variants are explained in the legend of Figure 2.
doi:10.1371/journal.pone.0042252.g004
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AR to other ligands [8], affect several AR-dependent processes
[2,32]. Steinkamp et al. reported that hormone-naı¨ve PCa tumor
samples had very few AR mutations suggesting that these
mutations offered little growth advantage and were in fact random
‘‘passenger’’ mutations [33]. The assay we used specifically selects
for AR mutations that affect receptor function [22]. We observed
a huge diversity of androgen deprivation therapy-induced AR
mutations, although very few were common to all AI variants and
a majority were not described [34]. Altogether, AI variants
illustrated the putative diversity of biological events associated with
hormone escape and underlined that an AR-dependent control
remains central in prostate cancers. Novel therapeutic approaches
targeting the AR pathways by inhibiting either the 17–20 lyase or
the translocation of the receptor towards the nucleus underlined
this key point [1]. Our last set of data is another alternative of
blocking AR pathways that could be addressed in clinics.
We examined Her-2/neu and p-AKT expression in PAC120 AI
variants to determine whether kinase and phosphorylation path-
ways were involved in the hormone escape, as shown by others
[15,18]. In clinical samples, Her-2/neu expression was elevated in
AI tumors [14,35] and reported as an early event in the androgen
dependence to independence switch [36]. The proposed mecha-
nism for the role of Her-2/neu in hormone escape is that this
kinase activates AR phosphorylation (via the MAPK pathway or
AKT pathway) [18,37], which in turn maintains AR integrity and
thus, its function in absence of testosterone. Lin HK et al., showed
that PI(3)K/Akt, but not PI(3)K/p70S6K signaling pathway can
modulate the AR transactivation. By using herceptin, we block the
PI(3)K pathway upstream which could explain reduction of tumor
escape [38].
Other alterations can contribute to a ligand-independent
activation of AR. Loss of PTEN, PI3K mutation, AKT1 and
AKT2 amplification may activate AKT kinase. Increase of
phospho-AKT levels was detected in bicatulamide-treated PCa
[39]. In our AI variants, Her-2/neu and p-AKT expression/
activation was increased and the preventive effect of trastuzumab-
or everolimus- degarelix combined treatments on hormone escape
demonstrates their key role. The Her-2/AKT and mTOR
pathways are targets accessible to new inhibitors; trastuzumab
has demonstrated its efficacy in Her-2/neu-amplified breast
cancer [40]. Wang et al demonstrated on prostate cancer cell line
that inhibition of mTORC1 and AR pathways by a combination
of rapamycin and bicatulamide led to apoptosis and could be
a therapeutic value in prostate cancer treatment [41]. A recent
study showed on LnCaP and a short term experiment the benefit
of the blockade of AR signaling in combination with the mTOR
pathways [42]. We report that these agents in combination with
castration greatly reduced androgen independence, co-adminis-
tration being required. In addition, strong support come from
a study where everolimus combined with an aromatase inhibitor
improved progression-free survival in patients with hormone-
receptor–positive advanced breast cancer previously treated with
nonsteroidal aromatase inhibitors [43].
Our data confirm that AR remains a central actor in PCa cell
survival, and our data suggest that androgen receptor can be
activated by alternative pathways resulting in androgen indepen-
dence. Finally, we showed that combination treatment of
castration with targeted molecular therapy significantly reduced
the risk of hormone escape. This study might have great
implication in the treatment of androgen dependent prostate
cancer and dual inhibition is worth exploring in the clinical setting.
Supporting Information
Figure S1 Schematic representation of the in vivo
treatment regimens.
(TIF)
Figure 5. PAC120 xenograft tumor response to combination treatment of castration plus tyrosine kinase inhibitors shown as A)
escape-free survival (Kaplan-Meier analysis) where the median time to hormone escape after continuous treatment with degarelix
(black square, full line) was 274 days and after combination of trastuzumab plus FE 200846 (cross, full line) was 351 days. B) tumor
growth curves as a function of time in the control group (white cercle, full line) and in groups receiving everolimus 2 mg/kg three times a week
(white diamond shape, dotted line), degarelix 10 mg/kg monthly (white square, full line), trastuzumab plus degarelix (cross, full line) or everolimus
plus degarelix (black diamond-shaped, full line).
doi:10.1371/journal.pone.0042252.g005
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Figure S2 Relative mRNA expression of androgen re-
ceptor (AR) (black bars) and intratumoral prostate-
specific antigen (PSA) (white bars) in androgen in-
dependent (AI) variants. *indicates variants with amplified
AR gene copy number. Abbreviations used to identify variants are
explained in the legend of Figure 2.
(TIF)
Figure S3 Hormone response profile in the AIde-a4
castration-resistant tumor. The responsiveness of the AR in
the AIde-a4 castration-resistant tumor was assessed by using the
yeast-based functional assay and compared with that of the wild-
type AR as described in Material and Methods. Histograms
represent aberrant responses obtained with 100 nM b-estradiol
(E2) and 1 mM cyproterone acetate (CPA) when compared with
the wild-type AR.
(TIF)
Figure S4 Constitutive activity of Q693X androgen
receptor variant. The nonsense mutation Q693X leads to
a truncated androgen receptor variant, which is deleted of the
entire ligand-binding domain and AF-2. When compared to the
ligand-dependent activity of the wild-type AR, the Q693X AR
variant demonstrated constitutive activity in the yeast-based AR
assay. Histograms represent the relative number of colonies
obtained in the presence of the indicated hormone or anti-
androgen to that obtained in the presence of 100 nM DHT. DHT,
dihydrotestosterone; And, androstenedione; Prog, progesterone; Bic, bicaluta-
mide; Flut, flutamide.
(TIF)
Table S1 Number of mice assigned to each treatment
group.
(DOC)
Table S2 In vivo PAC120 tumor response to different
hormone treatments.
(DOC)
Table S3 Results of the comparative genomic hybrid-
ization array of DNA from androgen-independent (AI)
tumors. Minimal regions were altered in more than 20% of AI
variants. *Regions on 1 p, 19 p and 19 q were associated with
a delayed time to hormone escape.
(DOC)
Table S4 Characteristics of the androgen-independent
(AI) variants. Data for AIde01 to AIde04 were obtained from
independent experiments (data not shown). Data for mRNA
expression (androgen receptor, AR) and tumoral prostate-specific
antigen (PSA), circulating PSA levels and Protein expression (see
last column) are relative to their mean expression in PAC120
tumors (units are arbitrary).
(DOC)
Methods S1
(DOC)
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